Pharmacy Times
JUNE 22, 2022
Even if the financial resources were available, there aren’t enough human resources in pharmacy to provide high-touch engagement to the millions of patients who suffer from common chronic diseases.
pharmaphorum
JUNE 22, 2022
The pandemic highlighted how fragile the global manufacturing network is, as supply of certain products was limited and regulatory inspections became difficult to carry out. Ben Hargreaves finds out how the issue of foreign manufacturing has become a major US political talking point and how this could influence the pressures facing the industry. In a global economy, across a number of industries, low-margin products are often manufactured in countries where labour is cheap.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 22, 2022
Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
pharmaphorum
JUNE 22, 2022
Pfizer has harnessed the expertise of health data specialist Truveta to provide close monitoring of safety and other signals for its products, including COVID-19 vaccine Comirnaty, almost in real-time. Truveta’s platform is based on electronic medical record data – updated daily – for more than 50 million people in the US, harvesting anonymised patient care information from tens of thousands of clinical care sites across 42 states.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
JUNE 22, 2022
Jardiance shows reduction of 50% compared with dipeptidyl peptidase-4 inhibitors and 30% compared with glucagon-like peptide 1 receptor agonists.
Outsourcing Pharma
JUNE 22, 2022
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
JUNE 22, 2022
AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class. Qulipta (atogepant) is already approved for prevention of episodic migraine – where attacks are less frequent – getting the green light from the FDA last September for this use a few months after Biohaven and Pfizer’s Nurtec ODT (rimegepant).
Pharmacy Times
JUNE 22, 2022
Vaccinations are a critical preventive vaccinations are a critical preventive health measure and are routinely recommended from an early age. Indeed, the first hepatitis B vaccine in the series can be administered within 12 to 24 hours of birth.
Pharmaceutical Technology
JUNE 22, 2022
BioMarin Pharmaceutical has obtained Japan’s Ministry of Health, Labor and Welfare (MHLW) approval of the registration for its Voxzogo (vosoritide) for injection to treat achondroplasia in children whose growth plates are not closed. A modified C-type natriuretic peptide (CNP), Voxzogo acts on achondroplasia’s underlying pathophysiology. It works by down-regulating fibroblast growth factor receptor 3 (FGFR3) signalling and subsequently boosting endochondral bone formation.
Pharmacy Times
JUNE 22, 2022
Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JUNE 22, 2022
Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the centrepiece of a 10-year agreement-in-principle between the biotech and the UK government – which has been rumoured to be on the cards for several months – that is worth in the region of £1 billion ($1.2 billion), according to a report in the Financial Times.
Pharmacy Times
JUNE 22, 2022
Data show significantly higher geometric mean titer ratios, meeting prespecified endpoints for superiority against the variant.
Board Vitals - Pharmacist
JUNE 22, 2022
As a physician, you are required to complete CME activities in order to maintain your certification. However, with so many CME activity types available, it can be difficult to select the activity that works best for you. Many providers offer enduring materials to help practitioners fulfill these requirements. What are CME enduring materials? How do you know if they are best for meeting your CME requirements?
Pharmacy Times
JUNE 22, 2022
Areas of focus include drug discrepancies during transitions of care, polypharmacy, and promotion of self-management.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JUNE 22, 2022
Six in 10 respondents to Health Union’s Spondyloarthritis In America 2021 survey said they feel other people in their lives don’t understand the risks of being immunocompromised. And they aren’t alone. Scientists estimate nearly 3% of people in the U.S. can be considered immunocompromised, meaning their immune system and their ability to fight infections and other diseases is weakened.
Pharmacy Times
JUNE 22, 2022
The survey results come as the ACIP evaluates data to provide guidance for flu vaccines in older adults.
pharmaphorum
JUNE 22, 2022
Dominance of the pneumococcal vaccine category is a race between Merck & Co and Pfizer, and while the latter is comfortably in front at the moment with its Prevnar franchise, Merck has multiple runners in the running. One of these – dubbed V116 – is a cocktail of 21 Streptococcus pneumoniae serotypes designed to have the most benefit in adult populations, and it has just cleared a phase 1/2 trial as it embarks on a phase 3 programme.
Pharmacy Times
JUNE 22, 2022
Imlunestrant is currently under investigation as monotherapy or in combination with other anticancer therapies for patients with estrogen receptor-positive, locally advanced or metastatic breast cancer and endometrial cancer.
pharmaphorum
JUNE 22, 2022
Novartis could lose years of patent protection in the US for its blockbuster multiple sclerosis therapy Gilenya, after a federal appeals verdict went against the company. The litigation revolves around US Patent No. 9,187,405, granted in 2015, which covers a dosing regimen for Gilenya (fingolimod) in relapsing-remitting MS. Gilenya is Novartis’ third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have st
Pharmacy Times
JUNE 22, 2022
Tocilizumab (Actemra) is indicated for treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
PharmExec
JUNE 22, 2022
Mr. Horvath, who brings over a decade of experience in pharmaceutical commercialization, will lead the commercialization of POINT’s pipeline.
Pharmacy Times
JUNE 22, 2022
By maintaining relationships, pharmacists can create a successful practice and pharmaceutical care services will expand.
Med Ed 101
JUNE 22, 2022
I am going to outline a common case of escalating dosages of levothyroxine. I beg you to ALWAYS look for binding interactions with levothyroxine when you see dose increases! KE is a 68-year-old female with a history of GERD, anemia, osteoarthritis, hypertension, and diabetes. Her current medication list includes: Metformin 500 mg TID Ferrous sulfate […].
Pharmacy Times
JUNE 22, 2022
Tecnu Rash Relief Spray treats skin irritation caused by sunburn, minor skin irritations, insect bites, and other minor skin issues.
Pharmaceutical Commerce
JUNE 22, 2022
Maria Kirsch points to three key objectives in building effective patient support programs.
Pharmacy Times
JUNE 22, 2022
PAPs can significantly reduce OOP costs for patients.
PharmExec
JUNE 22, 2022
Agency leaders seek to build public trust in science and gain support for regulation.
Pharmaceutical Commerce
JUNE 22, 2022
Agency will be reviewing laboratory study and CMC data on the bivalent jab that targets two strains of the SARS-CoV-2 virus.
Pharma Times
JUNE 22, 2022
Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer
The Luxe Pharmacist
JUNE 22, 2022
Cheers to THE largest sale of the year for one of my favorite skin care brands! 50% off with code THELUXEPHARMACIST is happening for ONE DAY ONLY June 23rd so act fast! FRÉ always has a money back guarantee so you truly have nothing to lose. I started using FRÉ products this winter and quickly fell in love with them. I have seen great results with these products which I’ll share more about below.
Pharma Times
JUNE 22, 2022
The MS Society responds as MS therapy Fampyra is rejected
Outsourcing Pharma
JUNE 22, 2022
The company has introduced a mobile application designed to streamline and automate training in a single platform for sponsors, CROs, and research sites.
Pharmaceutical Technology
JUNE 22, 2022
In October 2021, the World Health Organization (WHO) announced a target of fully vaccinating 70% of each country’s population against Covid-19 by the end of June 2022. At the time, while many high-income countries had already surpassed this goal, Covid-19 vaccination programmes in developing nations, particularly in Sub-Saharan Africa, had barely begun.
Expert insights. Personalized for you.
181 
Let's personalize your content